Novaliq, a German pharmaceutical company founded in 2007, is at the forefront of developing revolutionary ocular therapeutics to treat a range of eye diseases, using its proprietary EyeSol® technology. EyeSol® is the first and only water-free technology worldwide for ophthalmology products, providing a superior delivery system for drugs to penetrate the ocular surface, offering enhanced bioavailability and longer-lasting effects. With a focus on dry eye disease (DED), Novaliq has developed two EyeSol® entities that are in phase 3 clinical trials and have demonstrated superior clinical benefits. In this startup showcase, we explore how Novaliq is revolutionizing ocular therapeutics using EyeSol® technology.
Innovative Products and Pipeline
Novaliq has developed two innovative EyeSol® products for treating dry eye disease, NOV03 and CyclASol®, targeting evaporative and aqueous-deficient DED, respectively. NOV03 is the first drug developed to treat evaporative DED associated with Meibomian gland dysfunction, providing highly effective relief for patients. Clinical trials have demonstrated a significant improvement in DED symptoms such as dryness, grittiness, and burning sensation, with a quick onset of action and excellent tolerability profile. CyclASol® is an ophthalmic solution of 0.1% cyclosporine A in EyeSol®, an anti-inflammatory and immunomodulating drug for treating aqueous-deficient DED. CyclASol® has also demonstrated superior clinical benefits, improving tear production, reducing eye inflammation and increasing patients’ quality of life.
Novaliq’s pipeline of products includes the development of EyeSol®-based treatments for other ocular diseases such as glaucoma, macular edema, and retinal diseases. These products have the potential to offer superior delivery of drugs, improved bioavailability, and longer-lasting effects, compared to conventional eye drops.
International Recognition and Partnership
Novaliq has received numerous awards and recognition for its innovative EyeSol® technology, including being named the German Start-up of the Year in 2019. Novaliq’s products have also received regulatory approval in Europe, Australia, and New Zealand, with commercialization partnerships established in these regions.
Novaliq has established several partnerships with pharmaceutical companies and research institutions worldwide to further develop EyeSol® technology and products. In 2021, Novaliq announced a strategic partnership with Santen Pharmaceutical Co., Ltd., a leading global ophthalmology company, to develop and commercialize innovative ophthalmic treatments using EyeSol® technology. This partnership aims to accelerate the development of EyeSol®-based products for treating ocular diseases.
Conclusion
Novaliq, with its innovative EyeSol® technology, is a pioneer in developing effective and superior ocular therapeutics for treating a range of ocular diseases. The company’s focus on dry eye disease has resulted in the development of two EyeSol® entities, NOV03 and CyclASol®, which have demonstrated superior clinical benefits, providing much-needed relief for patients. With a pipeline of products in development and partnerships established worldwide, Novaliq is set to make a significant impact in the field of ocular therapeutics.
Website: https://www.novaliq.com/
Twitter: https://twitter.com/novaliq
Facebook: https://www.facebook.com/pages/Novaliq-GmbH/405640629612851
LinkedIn: https://www.linkedin.com/company/novaliq/
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
